Global Patent Index - EP 1455812 A2

EP 1455812 A2 20040915 - ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODY THERAPY FOR MULTIPLE SCLEROSIS TREATMENT

Title (en)

ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODY THERAPY FOR MULTIPLE SCLEROSIS TREATMENT

Title (de)

BEHANDLUNG MIT ANTI-CD40 MONOKLONALEM ANTIKÖRPER FÜR DIE BEHANDLUNG VON MULTIPLER SKLEROSE

Title (fr)

TRAITEMENT AUX ANTICORPS MONOCLONAUX ANTI-CD40 ANTAGONISTES UTILISE POUR TRAITER LA SCLEROSE EN PLAQUES

Publication

EP 1455812 A2 20040915 (EN)

Application

EP 02784651 A 20021126

Priority

  • US 0238164 W 20021126
  • US 33335501 P 20011126

Abstract (en)

[origin: WO03045978A2] The present invention is directed to a method for preventing or alleviating the symptons of MS by delivering to the central nervous system an interferon and an anti-CD40 antibody. Interferons include interferon- beta and its muteins such as IFN- beta ser17.

IPC 1-7

A61K 38/19; A61K 39/395; C07K 14/52; C07K 16/28

IPC 8 full level

A61K 38/21 (2006.01); A61K 39/395 (2006.01); A61P 1/04 (2006.01); A61P 25/00 (2006.01); A61P 37/02 (2006.01); C07K 16/28 (2006.01)

CPC (source: EP)

A61K 39/39541 (2013.01); A61P 1/04 (2017.12); A61P 25/00 (2017.12); A61P 37/02 (2017.12); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

DOCDB simple family (publication)

WO 03045978 A2 20030605; WO 03045978 A3 20030731; AU 2002346581 A1 20030610; AU 2002346581 A8 20030610; CA 2466931 A1 20030605; EP 1455812 A2 20040915; EP 1455812 A4 20060322; JP 2005510570 A 20050421

DOCDB simple family (application)

US 0238164 W 20021126; AU 2002346581 A 20021126; CA 2466931 A 20021126; EP 02784651 A 20021126; JP 2003547427 A 20021126